Atrium Therapeutics Inc stock is traded at $6.95, with a volume of 67,193. It is up +4.67% in the last 24 hours and down -8.67% over the past month. Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Previous Close:
$6.64
Open:
$6.70
24h Volume:
67,193
Relative Volume:
0.32
Market Cap:
$149.92M
Revenue:
$25.04M
Net Income/Loss:
-$64.73M
P/E Ratio:
-
EPS:
-$3.78
Net Cash Flow:
-$502.70M
1W Performance:
-7.33%
1M Performance:
-8.67%
6M Performance:
-46.33%
1Y Performance:
-90.20%
1-Day Range:
$6.65$6.97
1-Week Range:
$6.36$7.83
52-Week Range:
$6.36$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
Name
Atrium Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
858-401-7900Address
3020 CALLAN ROAD, SAN DIEGO, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS